Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SygeLIX-Coll-T for Chronic Keratitis
NCT05200000Phase 1Completed
- Sponsor
- TBF Génie Tissulaire
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SygeLIX-Coll-T in keratitis, sponsored by TBF Génie Tissulaire. Primary endpoint: Absence of aggravated inflammatory signs, worsening of visual acuity or other side effect at 40 days. Started Jan 2020; status: completed.
02
Drugs
SygeLIX-Coll-T
03
Conditions
keratitis
Beyond the preview
Go deeper on NCT05200000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200000.